Background: Real-world utilization data for evolocumab, the first proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitor to be introduced in Japan in 2016, to date are …

Monoclonal antibodies to proprotein convertase subtilisin-kexin type 9 (PCSK9) have been
shown to be effective in lowering LDL-cholesterol levels. The efficacy and safety of the …

Objective To describe the clinical characteristics, the reasons for initiating therapy, and the
effects of treatment in the initial phase of evolocumab availability in Lipid/Internal Medicine …

Abstract Purpose of Review To review the efficacy, safety, pharmacology, and
pharmacokinetics of evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) …

Introduction The aims of this study were to describe patient characteristics, lipid parameters,
lipid-lowering drug use, and safety of patients receiving evolocumab in a real-world clinical …

Despite the proven efficacy of statins, they often fail to achieve low-density lipoprotein (LDL)
cholesterol goals, especially in high-risk patients. Moreover, a large number of subjects …

Aims Limited data exist on low-density lipoprotein-cholesterol (LDL-C) level variability or
long-term persistence with the monoclonal antibody evolocumab in routine clinical practice …

Introduction: Evolocumab is a fully human monoclonal immunoglobulin G2 directed against
human proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered by …

Aims Some trials have reported diminished efficacy for statins in the elderly, and in women
compared with men. We examined the efficacy and safety of evolocumab by patient age and …

Background: Treatment with evolocumab reduces mean low-density lipoprotein cholesterol
(LDL-C) up to 75% and cardiovascular events by 16% in the first year and 25% thereafter …